Psoriatic Arthritis Market Forecast 2036: Next-Generation Biologics and Oral Targeted Therapies to Drive Market Growth Through 2036 - DelveInsight

DelveInsight's "Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast-2036" report provides an in-depth understanding of Psoriatic Arthritis, including historical and forecasted epidemiology as well as Psoriatic Arthritis market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Get a Free sample for the Psoriatic Arthritis Market Report:
https://www.delveinsight.com/report-store/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Facts of the Psoriatic Arthritis Market Report

• The Psoriatic Arthritis market is expected to grow at a significant CAGR during the forecast period (2026-2036).
• In May 2026, Affibody announced positive 52-week data from its global Phase IIb/III study of izokibep in Psoriatic Arthritis at the European Congress of Rheumatology (EULAR) 2026. The investigational therapy achieved the primary endpoint of ACR50 at Week 16 with high statistical significance.
• In March 2026, Sun Pharmaceutical announced that the US FDA accepted the supplemental Biologics License Application (sBLA) for tildrakizumab (ILUMYA) for adults with active Psoriatic Arthritis. The FDA action date is expected in October 2026.
• In March 2026, deucravacitinib (SOTYKTU) from Bristol Myers Squibb received US FDA approval for the treatment of adults with active Psoriatic Arthritis based on positive Phase III POETYK PsA-1 and POETYK PsA-2 trial results demonstrating significant improvements in ACR20 and Minimal Disease Activity responses.
• The currently approved Psoriatic Arthritis treatment landscape includes RINVOQ (upadacitinib), SOTYKTU (deucravacitinib), BIMZELX (bimekizumab), SKYRIZI (risankizumab), TREMFYA (guselkumab), and other targeted therapies.
• Emerging pipeline therapies such as Tildrakizumab (ILUMYA), Izokibep, Icotrokinra (JNJ-77242113), Zasocitinib (TAK-279), ALTB-168, Tulisokibart (MK-7240-015), and JNJ-88545223 are expected to reshape the treatment landscape during the forecast period.
• Psoriatic Arthritis is generally a progressive disease, with many patients developing irreversible structural joint damage over time if not treated adequately despite advances in biologic therapies.
• According to the National Psoriasis Foundation, approximately one in three people living with psoriasis also develops Psoriatic Arthritis.
• Nearly 70-85% of patients have mild-to-moderate disease, while approximately 15-25% progress to severe disease.
• The disease most commonly affects adults between 30 and 50 years of age and shows a nearly equal distribution between males and females, although disease manifestations differ between sexes.
• The treatment paradigm continues shifting from traditional TNF inhibitors toward IL-17 inhibitors, IL-23 inhibitors, TYK2 inhibitors, and oral targeted therapies, driven by improved efficacy across both joint and skin manifestations.
• Risankizumab (SKYRIZI) has emerged as a leading therapy in the Psoriatic Arthritis market due to its durable efficacy, favorable long-term safety profile, and increasing physician adoption.
• Novel biologics including izokibep and other IL-17 pathway inhibitors are being developed to improve tissue penetration, enhance treatment responses, and address refractory patient populations.
• Increasing biosimilar competition among TNF inhibitors is accelerating treatment switching toward newer IL-17 and IL-23 inhibitors, reshaping competitive dynamics across the Psoriatic Arthritis market.
• Despite significant therapeutic advances, many patients continue to experience persistent pain, fatigue, incomplete treatment responses, and progressive disease, highlighting the continued need for disease-modifying therapies, predictive biomarkers, and durable long-term treatment strategies.
• Globally, the prevalence of Psoriatic Arthritis is estimated at approximately 0.1-0.2%.
• Approximately 2.4 million people in the United States are living with Psoriatic Arthritis.
• More than 15% of individuals with psoriasis in the United States may have undiagnosed Psoriatic Arthritis.
• Around 20% of patients with psoriasis eventually develop Psoriatic Arthritis, although prevalence varies according to disease severity, age, and geographic region.
• Key Psoriatic Arthritis Companies include Bristol Myers Squibb, UBC, AbbVie, Johnson & Johnson, Sun Pharmaceutical Industries, Affibody Medical, Takeda Pharmaceuticals, AltruBio, Merck Sharp & Dohme, and others.
• Key Psoriatic Arthritis Therapies include Deucravacitinib (SOTYKTU), Bimekizumab (BIMZELX), Risankizumab (SKYRIZI), Upadacitinib (RINVOQ), Guselkumab (TREMFYA), Tildrakizumab (ILUMYA), Izokibep, Icotrokinra (JNJ-77242113), Zasocitinib (TAK-279), ALTB-168, Tulisokibart (MK-7240-015), JNJ-88545223, and others.
• The Psoriatic Arthritis market is expected to witness substantial growth during the forecast period owing to increasing disease awareness, earlier diagnosis, expanding use of biologics and targeted oral therapies, and the anticipated launch of several late-stage pipeline candidates.

Psoriatic Arthritis Overview

Psoriatic Arthritis is a chronic immune-mediated inflammatory disease that affects both the joints and skin and is closely associated with psoriasis. The disease is characterized by joint pain, swelling, stiffness, enthesitis, dactylitis, and varying degrees of axial involvement. Its clinical presentation is heterogeneous, ranging from mild peripheral arthritis to severe erosive joint disease that can significantly impair physical function and quality of life.
Early diagnosis is essential because irreversible structural damage may occur if treatment is delayed. Diagnosis is primarily clinical and supported by the CASPAR classification criteria, imaging techniques such as X-ray, ultrasound, and MRI, while laboratory investigations mainly help exclude other inflammatory arthritides, as no single diagnostic biomarker currently exists.

To Know in detail about the Psoriatic Arthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Psoriatic Arthritis Market Forecast -
https://www.delveinsight.com/report-store/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Psoriatic Arthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends of Psoriatic Arthritis across the seven major markets (7MM) from 2022 to 2036. It helps identify key disease trends by evaluating published literature, epidemiological studies, and expert opinions. The section also provides a comprehensive assessment of the diagnosed patient population, disease burden, and future epidemiological outlook.

Psoriatic Arthritis Epidemiology Segmentation

• Total Prevalent Cases of Psoriatic Arthritis
• Total Diagnosed Prevalent Cases of Psoriatic Arthritis
• Psoriatic Arthritis Diagnosed Prevalent Cases by Gender
• Psoriatic Arthritis Diagnosed Prevalent Cases by Age
• Psoriatic Arthritis Diagnosed Prevalent Cases by Severity
• Treated Cases of Psoriatic Arthritis

Download the report to understand which factors are driving Psoriatic Arthritis epidemiology trends @ Psoriatic Arthritis Epidemiology Forecast -
https://www.delveinsight.com/report-store/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Psoriatic Arthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the adoption rate of recently approved therapies and potential drugs expected to enter the Psoriatic Arthritis market during the forecast period.
Moreover, the therapeutics assessment section helps identify therapies expected to achieve the fastest uptake and the factors contributing to their commercial success.
The report also covers Psoriatic Arthritis pipeline development activities, providing detailed insights into therapeutic candidates across different stages of development and the key companies advancing innovative treatment options.

Psoriatic Arthritis Therapies and Key Companies

• Deucravacitinib (SOTYKTU): Bristol Myers Squibb
• Bimekizumab (BIMZELX): UBC
• Risankizumab (SKYRIZI): AbbVie
• Upadacitinib (RINVOQ): AbbVie
• Guselkumab (TREMFYA): Johnson & Johnson
• Tildrakizumab (ILUMYA): Sun Pharmaceutical Industries
• Izokibep: Affibody Medical
• Icotrokinra (JNJ-77242113): Johnson & Johnson
• Zasocitinib (TAK-279): Takeda Pharmaceuticals
• ALTB-168: AltruBio
• Tulisokibart (MK-7240-015): Merck Sharp & Dohme
• JNJ-88545223: Johnson & Johnson

Discover more about therapies set to grab major Psoriatic Arthritis market share @ Psoriatic Arthritis Treatment Market -
https://www.delveinsight.com/report-store/psoriatic-arthritis-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Psoriatic Arthritis Market Drivers

• Rising prevalence of psoriasis and improved screening are contributing to earlier diagnosis and expanding the treated patient population across major markets.
• Increasing adoption of biologics and targeted therapies, including IL-17, IL-23, JAK, and TYK2 inhibitors, is improving disease management and driving market growth.
• A robust late-stage pipeline featuring novel biologics and oral targeted therapies is expected to expand treatment options and strengthen market competition.
• Growing physician preference for precision therapies that effectively manage both joint and skin manifestations is accelerating the uptake of next-generation treatments.
• Continuous clinical innovation and favorable regulatory progress are supporting the development of safer and more effective therapies for patients with Psoriatic Arthritis.

Psoriatic Arthritis Market Barriers

• A considerable proportion of patients continue to experience incomplete treatment response, persistent pain, fatigue, and disease progression despite available therapies.
• Long-term safety concerns associated with biologic and targeted therapies remain an important challenge for chronic disease management.
• The absence of reliable predictive biomarkers limits personalized treatment selection and optimal therapeutic outcomes.
• High treatment costs and reimbursement challenges continue to restrict patient access to advanced therapies in several markets.
• Increasing competition from biosimilars is creating pricing pressure across established biologic therapies.

Scope of the Psoriatic Arthritis Market Report

• Study Period: 2022-2036
• Coverage: 7MM
• Key Psoriatic Arthritis Companies: Bristol Myers Squibb, UBC, AbbVie, Johnson & Johnson, Sun Pharmaceutical Industries, Affibody Medical, Takeda Pharmaceuticals, AltruBio, Merck Sharp & Dohme, and others.
• Key Psoriatic Arthritis Therapies: Deucravacitinib (SOTYKTU), Bimekizumab (BIMZELX), Risankizumab (SKYRIZI), Upadacitinib (RINVOQ), Guselkumab (TREMFYA), Tildrakizumab (ILUMYA), Izokibep, Icotrokinra (JNJ-77242113), Zasocitinib (TAK-279), ALTB-168, Tulisokibart (MK-7240-015), JNJ-88545223, and others.
• Psoriatic Arthritis Therapeutic Assessment: Current marketed therapies and emerging therapies.
• Psoriatic Arthritis Market Dynamics: Psoriatic Arthritis market drivers and Psoriatic Arthritis market barriers.
• Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis, Reimbursement Analysis, Market Attractiveness Assessment, and KOL Insights.
• Psoriatic Arthritis Unmet Needs, KOL Views, Analyst's Views, and Market Access & Reimbursement Analysis.

Table of Contents

1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Methodology of Psoriatic Arthritis
6. Psoriatic Arthritis Market Overview at a Glance
7. Disease Background and Overview of Psoriatic Arthritis
8. Epidemiology and Patient Population of Psoriatic Arthritis
9. Patient Journey of Psoriatic Arthritis
10. Marketed Therapies
11. Emerging Therapies
12. Psoriatic Arthritis: Seven Major Market Analysis
13. Unmet Needs of Psoriatic Arthritis
14. SWOT Analysis of Psoriatic Arthritis
15. KOL Views of Psoriatic Arthritis
16. Market Access and Reimbursement of Psoriatic Arthritis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.